Recruiting
Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with ADC therapy
ClinicalTrials.gov IDNCT06909604
PhaseNA
Enrollment50
SponsorPeking University Cancer Hospital & Institute
Age18 Years
SexALL
Conditions studied
Breast Cancer
About this study
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with ADC therapy
Interventions
- Radiation: HER2 expression of PET imaging — Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in breast patients treated with ADC therapy
Primary outcomes
- Changes in SUVmax before and after treatment (Before treatment, 9 weeks after treatment, before surgery)
Eligibility information
Inclusion Criteria:
1. Aged ≥18 years old; ECOG 0 or 1;
2. Patients with HER2 positive or low tumors;
3. Receives neoadjuvant therapy
4. Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions;
5. Life expectancy \> 3 months -
Exclusion Criteria:
1. Significant hepatic or renal dysfunction;
2. Is pregnant or ready to pregnant;
3. Cannot keep their states for half an hour;
4. Refused to join the clinical research;
5. Suffering from claustrophobia or other mental disorders;
6. Any other situation that researchers considered it unsuitable to participate in the trial.
Study locations
- Peking University Cancer Hospital & Institute, Beijing, 100142 China
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.